GBT Grupo Biotoscana

GBT Grupo Biotoscana is rated 3 out of 5 in the category latam specialty pharmaceutical company. Read and write reviews about GBT Grupo Biotoscana. We are the first Latin American biopharmaceutical company based on innovation. We develop, manufacture and commercialize advanced medicines, aimed at treating truly unmet medical needs. Headquartered in Montevideo, Uruguay and with presence in 10 countries throughout the region, GBT offers an unparalleled infrastructure among its peers. We are a team of more than 600 scientists, doctors, pharmacists, regulatory professionals, sales and marketing experts, access specialists and dedicated support people spread throughout the region who make their lives'​ purpose to enhance lives and restore hopes to patients with severe and debilitating conditions. We focus on products that make a difference for doctors'​ practices and transform lives in profound and meaningful ways. Our main areas of operations are oncology and, onco-hematology, severe infectious diseases, specialty treatments, immunology and inflammation and orphan and rare diseases. GBT embraces Open Innovation at its core. A large portion of GBT's pipeline is sourced by partnering with biotechnology and other pharmaceutical companies worldwide. We complement this process with our own proprietary R&D efforts to drive strong R&D productivity and deliver truly innovative therapies that transform lives and restore hopes across the Latin American region. As a result, GBT's portfolio of medicines is comprised of truly cutting-edge technology that makes a difference for more than 200,000 doctors and more than 800,000 patients every year. Patients that can aspire to receive the benefits of truly modern medicine and, more importantly, to live longer and more meaningful lives.